Solara Active Pharma Q1 FY27: Revenue up 20% YoY

Key takeaway from the Q1 FY27 update

Solara Active Pharma Sciences Ltd reported a stronger year-on-year quarter in Q1 FY27, with management highlighting improved profitability and a reduction in net debt. The company discussed its performance in an earnings conference call held on July 23, 2026, covering unaudited results for the quarter ended June 30, 2026. Overall revenue was reported at INR384 crore, up 20% year-on-year, while EBITDA rose 10% year-on-year to INR63.5 crore. Profit after tax (PAT) increased 55% year-on-year to INR16.3 crore, which management said was the highest EBITDA and PAT delivered in the last 18 quarters. Alongside the headline numbers, the call also pointed to raw material and supply challenges that affected gross margins quarter-on-quarter. The company also disclosed that the audio recording of the earnings call was uploaded to its website as part of regulatory compliance.

What management said on revenue and profitability

On the earnings call, management stated that Q1 FY27 revenues stood at INR384 crore, representing 20% year-on-year growth. EBITDA was reported at INR63.5 crore, up 10% year-on-year, and PAT was INR16.3 crore, up 55% year-on-year. The company described this as the strongest EBITDA and PAT performance over the last 18 quarters. Management also said these results reflected the strength of its core business.

In the same discussion, the company indicated that gross margins were marginally lower on a quarter-on-quarter basis. It attributed the pressure to raw material pricing and supply challenges, which it said were triggered by the West Asia crisis. Despite those pressures, Solara reported an EBITDA margin of 17%, and referenced an improvement in EBITDA margin by 80 basis points quarter-on-quarter in the provided data.

Consolidated numbers: income, operations and other income

Solara’s consolidated total income for Q1 FY27 was reported at INR384.29 crore, a year-on-year increase of 20.04% from INR320.13 crore in Q1 FY26. On a sequential basis, total income declined 1.96% from INR391.98 crore in Q4 FY26. Revenue from operations was INR381.60 crore, up 19.57% year-on-year versus INR319.15 crore, and down 1.47% quarter-on-quarter from INR387.29 crore.

Other income in Q1 FY27 was INR2.69 crore, compared with INR0.98 crore in Q1 FY26 and INR4.69 crore in Q4 FY26. Profit before tax (PBT) was reported at INR16.31 crore, up 55.04% year-on-year from INR10.52 crore. The same update also reported a 69.90% quarter-on-quarter increase in PBT from INR8.74 crore in Q4 FY26 (before exceptional items).

Base business performance and gross margin details

Solara reported base business revenue of INR307 crore in Q1 FY27, up 24% year-on-year. Gross margin was reported at INR158 crore, up 10% year-on-year. Base business EBITDA was reported at INR72 crore, up 8% year-on-year, despite what management described as cost pressures from higher raw material prices.

The update also flagged the Ibuprofen business EBITDA margin at negative 12%. The company did not provide further segment-level numbers in the provided excerpt, but the negative margin indicates that the Ibuprofen line remained a drag on profitability during the quarter.

Balance sheet update: net debt and leverage

Solara reported net debt reduction of INR135 crore during the quarter. Net debt was stated at INR479 crore as of June 30. The company also reported a net debt-to-EBITDA multiple of 1.9x. These figures are closely tracked by investors because they provide a clearer picture of leverage as operating performance improves.

In the same broader results summary, the company also disclosed progress on a rights issue. As of June 30, 2026, it had raised INR442.73 crore out of a total rights issue size of INR449.95 crore.

Regulatory disclosure and earnings call access

Solara made a regulatory disclosure regarding the Q1 FY27 earnings call, stating that the audio recording of the call held on July 23, 2026 at 16:00 IST had been uploaded to its website. The disclosure referenced compliance with Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The recording was made available under the Investor Relations section, within Stock Exchange Communication and Investor Update categories.

The company also indicated that the transcript of the call would be made available in about a week’s time on its website. Separately, the provided text repeatedly notes that readers can refer to the full earnings call transcript for the complete discussion.

Financial snapshot table (Q1 FY27)

Why these numbers matter for investors

The quarter combines three signals that equity and credit investors typically focus on: year-on-year revenue growth, margin performance, and leverage movement. Solara’s reported EBITDA margin of 17%, alongside year-on-year EBITDA growth and a sharp rise in PAT, indicates that profitability improved faster than revenue. At the same time, management acknowledged that quarter-on-quarter gross margins faced pressure due to raw material pricing and supply constraints linked to the West Asia situation, which helps frame why operating metrics can move differently across periods.

Separately, the reduction in net debt by INR135 crore and the reported net debt-to-EBITDA of 1.9x provide a lens into how cash flows, funding actions, and profitability are translating into balance sheet outcomes. The rights issue update, with INR442.73 crore raised out of INR449.95 crore as of June 30, 2026, adds another factual datapoint on the company’s funding position during the period.

Conclusion

Solara Active Pharma Sciences reported Q1 FY27 revenue of about INR384 crore with year-on-year growth of 20%, EBITDA of INR63.5 crore, and PAT of INR16.3 crore, alongside an EBITDA margin of 17%. The quarter also included a net debt reduction of INR135 crore, taking net debt to INR479 crore as of June 30 and a net debt-to-EBITDA multiple of 1.9x. The company has made the earnings call audio available on its website under its Investor Relations section and indicated that the transcript would be posted subsequently.